Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2026 | $46.00 | Outperform | Evercore ISI |
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
S-8 - Damora Therapeutics, Inc. (0001800315) (Filer)
10-K - Damora Therapeutics, Inc. (0001800315) (Filer)
Evercore ISI initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $46.00
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora's Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants made on March 24,
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors. "We are excited to welcome Jen to Damora as we accel
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) ("Damora" or the "Company") (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. "At Damora Therapeuti
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors. "We are excited to welcome Jen to Damora as we accel